Company AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Pharmaceuticals

Market Closed - Nasdaq 21:15:00 03/05/2024 BST 5-day change 1st Jan Change
76.35 USD +0.73% Intraday chart for AstraZeneca PLC +1.57% +13.36%

Business Summary

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (4.4%).

Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Number of employees: 89,900

Sales per Business

GBP in Million2022Weight2023Weight Delta
Oncology
37.4 %
11,878 33.0 % 13,793 37.4 % +16.12%
Cardiovascular, Renal and Metabolism
23.1 %
7,459 20.7 % 8,515 23.1 % +14.16%
Rare Disease
16.9 %
5,726 15.9 % 6,246 16.9 % +9.08%
Respiratory and Immunology
13.3 %
4,680 13.0 % 4,913 13.3 % +4.97%
Alliance
3.1 %
- - 1,149 3.1 % -
Other Medicines
2.6 %
1,319 3.7 % 946 2.6 % -28.29%
Vaccines and Immune Therapies
2.2 %
3,845 10.7 % 814 2.2 % -78.83%
Collaboration
1.3 %
1,098 3.1 % 478 1.3 % -56.50%

Sales per region

GBP in Million2022Weight2023Weight Delta
United States
39.6 %
14,027 39.0 % 14,578 39.6 % +3.93%
China
12.8 %
4,662 12.9 % 4,724 12.8 % +1.32%
Japan
7.9 %
3,236 9.0 % 2,928 7.9 % -9.51%
United Kingdom
7.4 %
2,530 7.0 % 2,709 7.4 % +7.07%
Other Rest of Europe
6.8 %
2,197 6.1 % 2,502 6.8 % +13.89%
Germany
4.6 %
1,544 4.3 % 1,689 4.6 % +9.36%
Other Asia, Africa and Australasia
4.5 %
1,953 5.4 % 1,645 4.5 % -15.77%
Sweden
3.7 %
1,397 3.9 % 1,371 3.7 % -1.89%
Other Americas
3.7 %
954 2.6 % 1,354 3.7 % +41.94%
France
2.5 %
899 2.5 % 927 2.5 % +3.12%
Canada
2.1 %
947 2.6 % 778 2.1 % -17.82%
Spain
1.8 %
599 1.7 % 681 1.8 % +13.73%
Italy
1.8 %
597 1.7 % 654 1.8 % +9.61%
Australia
0.9 %
464 1.3 % 314 0.9 % -32.32%

Managers

Managers TitleAgeSince
Chief Executive Officer 64 30/09/12
Director of Finance/CFO 50 31/07/21
Chief Tech/Sci/R&D Officer 56 31/12/19
Chief Tech/Sci/R&D Officer - 31/07/23
Chief Tech/Sci/R&D Officer 60 -
Chief Tech/Sci/R&D Officer - 17/05/23
Chief Operating Officer 53 31/05/15
Compliance Officer - 31/12/94
Corporate Officer/Principal 63 31/12/01
Corporate Officer/Principal - 31/12/00

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 30/09/17
Corporate Officer/Principal 59 31/01/13
Director/Board Member 63 26/04/17
Director/Board Member 68 31/03/99
Corporate Officer/Principal 71 31/05/13
Director/Board Member 66 31/07/21
Chairman 67 31/08/19
Chief Executive Officer 64 30/09/12
Director/Board Member 64 30/11/17
Director of Finance/CFO 50 31/07/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,550,235,025 1,495,910,888 ( 96.50 %) 0 96.50 %

Shareholders

NameEquities%Valuation
BlackRock Investment Management (UK) Ltd.
4.420 %
68,512,693 4.420 % 9 242 M $
Wellington Management Co. LLP
4.201 %
65,120,892 4.201 % 8 784 M $
The Vanguard Group, Inc.
3.593 %
55,698,000 3.593 % 7 513 M $
Investor AB (Investment Company)
3.328 %
51,587,810 3.328 % 6 959 M $
Norges Bank Investment Management
2.216 %
34,357,000 2.216 % 4 634 M $
BlackRock Fund Advisors
1.918 %
29,736,171 1.918 % 4 011 M $
BlackRock Advisors (UK) Ltd.
1.418 %
21,987,529 1.418 % 2 966 M $
Swedbank Robur Fonder AB
1.096 %
16,986,070 1.096 % 2 291 M $
Legal & General Investment Management Ltd.
0.9998 %
15,499,242 0.9998 % 2 091 M $
BlackRock Advisors LLC
0.9901 %
15,349,305 0.9901 % 2 070 M $
NameEquities%Valuation
T. Rowe Price International Ltd.
1.686 %
52,269,524 1.686 % 3 541 M $
Wellington Management Co. LLP
1.595 %
49,444,180 1.595 % 3 350 M $
PRIMECAP Management Co.
1.386 %
42,987,075 1.386 % 2 912 M $
Capital Research & Management Co. (International Investors)
1.122 %
34,782,762 1.122 % 2 357 M $
Fidelity Management & Research Co. LLC
0.6877 %
21,321,999 0.6877 % 1 445 M $
Jennison Associates LLC
0.5572 %
17,276,282 0.5572 % 1 170 M $
Sanders Capital LLC
0.4736 %
14,684,066 0.4736 % 995 M $
GQG Partners LLC
0.4470 %
13,858,383 0.4470 % 939 M $
Eaton Vance Management
0.4041 %
12,530,160 0.4041 % 849 M $
Merrill Lynch International
0.3772 %
11,695,224 0.3772 % 792 M $
NameEquities%Valuation
Caixa DTVM SA
0.002924 %
272,113 0.002924 % 3 M $

Holdings

NameEquities%Valuation
18,750,000 75.00% 1,196,097,188 $
32,100,518 9.06% 802,167,869 $
108,923,023 37.58% 678,032,747 $
71,065,878 16.81% 57,455,341 $
16,000,000 22.30% 42,992,640 $
4,011,215 4.86% 18,010,355 $
7,485,500 9.26% 17,664,283 $
3,584,230 3.63% 655,914 $
884,956 1.99% 69,027 $

Company contact information

AstraZeneca PLC

Cambridge Biomedical Campus 1 Francis Crick Avenue

CB2 0AA, Cambridge

+44 20 3749 5000

http://www.astrazeneca.co.uk
address AstraZeneca PLC(AZN)

Group companies

NameCategory and Sector
Miscellaneous Commercial Services
Pharmaceuticals: Major
Miscellaneous Commercial Services
Insurance Brokers/Services
Pharmaceuticals: Major
Astrazeneca Holdings BV
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Astrazeneca Treasury BV

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2 USD
Average target price
164.5 USD
Spread / Average Target
+8.76%
Consensus